In this interview, Firefly VR founder Shel Mann discusses how immersive technology can help prepare patients for psychedelic therapies, and the integration of virtual tools into mainstream healthcare.
The early results of a COMPASS Pathways clinical trial quell some concerns related to the safety of psychedelic therapy for individuals with bipolar disorder.
As psychedelic-assisted therapies near FDA approval, questions remain about cost, who’s paying, and how much it saves patients and insurers in the long run.
In an era where thought leaders are minted by social media metrics, some influencers may be one viral video away from being tomorrow’s psychedelic luminaries.